Global Graft Versus Host Disease (GVHD) Treatment Market Research Report 2023

Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain types of white blood cells. This is caused due to the transplanted cells (graft) see recipient’s body (host) as exotic, thus transplanted cells attack the host body.

The global Graft Versus Host Disease (GVHD) Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The growing number of organ transplantation cases as one of the major factors that will have a positive impact on the growth of the market. The rise in chronic diseases across the globe has led to the growth in the need for organ transplantation. It has been observed that in 2015, the US witnessed more than 30,000 organ transplants cases, which has increased about 5% when compared to the previous year. Similarly, countries such as Australia also witnesses increasing cases of organ transplantation. This rising number of organ transplants will subsequently augment the growth prospects of the GVHD treatment market.

This report aims to provide a comprehensive presentation of the global market for Graft Versus Host Disease (GVHD) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Graft Versus Host Disease (GVHD) Treatment.

The Graft Versus Host Disease (GVHD) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Graft Versus Host Disease (GVHD) Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Graft Versus Host Disease (GVHD) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Graft Versus Host Disease (GVHD) Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Monoclonal Antibodies

1.2.3 MTOR Inhibitors

1.2.4 Tyrosine Kinase Inhibitors

1.2.5 Thalidomide

1.2.6 Etanercept

1.3 Market by Application

1.3.1 Global Graft Versus Host Disease (GVHD) Treatment Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Acute Graft Versus Host Disease (aGvHD)

1.3.3 Chronic Graft Versus Host Disease (cGvHD)

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Graft Versus Host Disease (GVHD) Treatment Market Perspective (2018-2029)

2.2 Graft Versus Host Disease (GVHD) Treatment Growth Trends by Region

2.2.1 Global Graft Versus Host Disease (GVHD) Treatment Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Graft Versus Host Disease (GVHD) Treatment Historic Market Size by Region (2018-2023)

2.2.3 Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Region (2024-2029)

2.3 Graft Versus Host Disease (GVHD) Treatment Market Dynamics

2.3.1 Graft Versus Host Disease (GVHD) Treatment Industry Trends

2.3.2 Graft Versus Host Disease (GVHD) Treatment Market Drivers

2.3.3 Graft Versus Host Disease (GVHD) Treatment Market Challenges

2.3.4 Graft Versus Host Disease (GVHD) Treatment Market Restraints

3.1 Global Top Graft Versus Host Disease (GVHD) Treatment Players by Revenue

3.1.1 Global Top Graft Versus Host Disease (GVHD) Treatment Players by Revenue (2018-2023)

3.1.2 Global Graft Versus Host Disease (GVHD) Treatment Revenue Market Share by Players (2018-2023)

3.2 Global Graft Versus Host Disease (GVHD) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Graft Versus Host Disease (GVHD) Treatment Revenue

3.4 Global Graft Versus Host Disease (GVHD) Treatment Market Concentration Ratio

3.4.1 Global Graft Versus Host Disease (GVHD) Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Graft Versus Host Disease (GVHD) Treatment Revenue in 2022

3.5 Graft Versus Host Disease (GVHD) Treatment Key Players Head office and Area Served

3.6 Key Players Graft Versus Host Disease (GVHD) Treatment Product Solution and Service

3.7 Date of Enter into Graft Versus Host Disease (GVHD) Treatment Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Graft Versus Host Disease (GVHD) Treatment Historic Market Size by Type (2018-2023)

4.2 Global Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Type (2024-2029)

5.1 Global Graft Versus Host Disease (GVHD) Treatment Historic Market Size by Application (2018-2023)

5.2 Global Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Application (2024-2029)

6.1 North America Graft Versus Host Disease (GVHD) Treatment Market Size (2018-2029)

6.2 North America Graft Versus Host Disease (GVHD) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2018-2023)

6.4 North America Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Graft Versus Host Disease (GVHD) Treatment Market Size (2018-2029)

7.2 Europe Graft Versus Host Disease (GVHD) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2018-2023)

7.4 Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size (2018-2029)

8.2 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Region (2018-2023)

8.4 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Graft Versus Host Disease (GVHD) Treatment Market Size (2018-2029)

9.2 Latin America Graft Versus Host Disease (GVHD) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2018-2023)

9.4 Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size (2018-2029)

10.2 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2018-2023)

10.4 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Bristol-Myers Squibb

11.1.1 Bristol-Myers Squibb Company Detail

11.1.2 Bristol-Myers Squibb Business Overview

11.1.3 Bristol-Myers Squibb Graft Versus Host Disease (GVHD) Treatment Introduction

11.1.4 Bristol-Myers Squibb Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

11.1.5 Bristol-Myers Squibb Recent Development

11.2 Abbott

11.2.1 Abbott Company Detail

11.2.2 Abbott Business Overview

11.2.3 Abbott Graft Versus Host Disease (GVHD) Treatment Introduction

11.2.4 Abbott Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

11.2.5 Abbott Recent Development

11.3 AbbVie

11.3.1 AbbVie Company Detail

11.3.2 AbbVie Business Overview

11.3.3 AbbVie Graft Versus Host Disease (GVHD) Treatment Introduction

11.3.4 AbbVie Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

11.3.5 AbbVie Recent Development

11.4 Allergan

11.4.1 Allergan Company Detail

11.4.2 Allergan Business Overview

11.4.3 Allergan Graft Versus Host Disease (GVHD) Treatment Introduction

11.4.4 Allergan Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

11.4.5 Allergan Recent Development

11.5 Anterogen

11.5.1 Anterogen Company Detail

11.5.2 Anterogen Business Overview

11.5.3 Anterogen Graft Versus Host Disease (GVHD) Treatment Introduction

11.5.4 Anterogen Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

11.5.5 Anterogen Recent Development

11.6 Astellas Pharma

11.6.1 Astellas Pharma Company Detail

11.6.2 Astellas Pharma Business Overview

11.6.3 Astellas Pharma Graft Versus Host Disease (GVHD) Treatment Introduction

11.6.4 Astellas Pharma Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

11.6.5 Astellas Pharma Recent Development

11.7 Athersys

11.7.1 Athersys Company Detail

11.7.2 Athersys Business Overview

11.7.3 Athersys Graft Versus Host Disease (GVHD) Treatment Introduction

11.7.4 Athersys Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

11.7.5 Athersys Recent Development

11.8 Caladrius

11.8.1 Caladrius Company Detail

11.8.2 Caladrius Business Overview

11.8.3 Caladrius Graft Versus Host Disease (GVHD) Treatment Introduction

11.8.4 Caladrius Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

11.8.5 Caladrius Recent Development

11.9 Eli Lilly

11.9.1 Eli Lilly Company Detail

11.9.2 Eli Lilly Business Overview

11.9.3 Eli Lilly Graft Versus Host Disease (GVHD) Treatment Introduction

11.9.4 Eli Lilly Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

11.9.5 Eli Lilly Recent Development

11.10 GlaxoSmithKline

11.10.1 GlaxoSmithKline Company Detail

11.10.2 GlaxoSmithKline Business Overview

11.10.3 GlaxoSmithKline Graft Versus Host Disease (GVHD) Treatment Introduction

11.10.4 GlaxoSmithKline Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

11.10.5 GlaxoSmithKline Recent Development

11.11 Glenmark

11.11.1 Glenmark Company Detail

11.11.2 Glenmark Business Overview

11.11.3 Glenmark Graft Versus Host Disease (GVHD) Treatment Introduction

11.11.4 Glenmark Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

11.11.5 Glenmark Recent Development

11.12 Kadmon Holdings

11.12.1 Kadmon Holdings Company Detail

11.12.2 Kadmon Holdings Business Overview

11.12.3 Kadmon Holdings Graft Versus Host Disease (GVHD) Treatment Introduction

11.12.4 Kadmon Holdings Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

11.12.5 Kadmon Holdings Recent Development

11.13 Osiris Therapeutics

11.13.1 Osiris Therapeutics Company Detail

11.13.2 Osiris Therapeutics Business Overview

11.13.3 Osiris Therapeutics Graft Versus Host Disease (GVHD) Treatment Introduction

11.13.4 Osiris Therapeutics Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

11.13.5 Osiris Therapeutics Recent Development

11.14 Sanofi

11.14.1 Sanofi Company Detail

11.14.2 Sanofi Business Overview

11.14.3 Sanofi Graft Versus Host Disease (GVHD) Treatment Introduction

11.14.4 Sanofi Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

11.14.5 Sanofi Recent Development

11.15 Takeda

11.15.1 Takeda Company Detail

11.15.2 Takeda Business Overview

11.15.3 Takeda Graft Versus Host Disease (GVHD) Treatment Introduction

11.15.4 Takeda Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

11.15.5 Takeda Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Graft Versus Host Disease (GVHD) Treatment Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Monoclonal Antibodies

    Table 3. Key Players of MTOR Inhibitors

    Table 4. Key Players of Tyrosine Kinase Inhibitors

    Table 5. Key Players of Thalidomide

    Table 6. Key Players of Etanercept

    Table 7. Global Graft Versus Host Disease (GVHD) Treatment Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 8. Global Graft Versus Host Disease (GVHD) Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 9. Global Graft Versus Host Disease (GVHD) Treatment Market Size by Region (2018-2023) & (US$ Million)

    Table 10. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Region (2018-2023)

    Table 11. Global Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 12. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Region (2024-2029)

    Table 13. Graft Versus Host Disease (GVHD) Treatment Market Trends

    Table 14. Graft Versus Host Disease (GVHD) Treatment Market Drivers

    Table 15. Graft Versus Host Disease (GVHD) Treatment Market Challenges

    Table 16. Graft Versus Host Disease (GVHD) Treatment Market Restraints

    Table 17. Global Graft Versus Host Disease (GVHD) Treatment Revenue by Players (2018-2023) & (US$ Million)

    Table 18. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Players (2018-2023)

    Table 19. Global Top Graft Versus Host Disease (GVHD) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Graft Versus Host Disease (GVHD) Treatment as of 2022)

    Table 20. Ranking of Global Top Graft Versus Host Disease (GVHD) Treatment Companies by Revenue (US$ Million) in 2022

    Table 21. Global 5 Largest Players Market Share by Graft Versus Host Disease (GVHD) Treatment Revenue (CR5 and HHI) & (2018-2023)

    Table 22. Key Players Headquarters and Area Served

    Table 23. Key Players Graft Versus Host Disease (GVHD) Treatment Product Solution and Service

    Table 24. Date of Enter into Graft Versus Host Disease (GVHD) Treatment Market

    Table 25. Mergers & Acquisitions, Expansion Plans

    Table 26. Global Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2018-2023) & (US$ Million)

    Table 27. Global Graft Versus Host Disease (GVHD) Treatment Revenue Market Share by Type (2018-2023)

    Table 28. Global Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 29. Global Graft Versus Host Disease (GVHD) Treatment Revenue Market Share by Type (2024-2029)

    Table 30. Global Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2018-2023) & (US$ Million)

    Table 31. Global Graft Versus Host Disease (GVHD) Treatment Revenue Market Share by Application (2018-2023)

    Table 32. Global Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 33. Global Graft Versus Host Disease (GVHD) Treatment Revenue Market Share by Application (2024-2029)

    Table 34. North America Graft Versus Host Disease (GVHD) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 35. North America Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2018-2023) & (US$ Million)

    Table 36. North America Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2024-2029) & (US$ Million)

    Table 37. Europe Graft Versus Host Disease (GVHD) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 38. Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2018-2023) & (US$ Million)

    Table 39. Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2024-2029) & (US$ Million)

    Table 40. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 41. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Region (2018-2023) & (US$ Million)

    Table 42. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size by Region (2024-2029) & (US$ Million)

    Table 43. Latin America Graft Versus Host Disease (GVHD) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 44. Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2018-2023) & (US$ Million)

    Table 45. Latin America Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2024-2029) & (US$ Million)

    Table 46. Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 47. Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2018-2023) & (US$ Million)

    Table 48. Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2024-2029) & (US$ Million)

    Table 49. Bristol-Myers Squibb Company Detail

    Table 50. Bristol-Myers Squibb Business Overview

    Table 51. Bristol-Myers Squibb Graft Versus Host Disease (GVHD) Treatment Product

    Table 52. Bristol-Myers Squibb Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023) & (US$ Million)

    Table 53. Bristol-Myers Squibb Recent Development

    Table 54. Abbott Company Detail

    Table 55. Abbott Business Overview

    Table 56. Abbott Graft Versus Host Disease (GVHD) Treatment Product

    Table 57. Abbott Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023) & (US$ Million)

    Table 58. Abbott Recent Development

    Table 59. AbbVie Company Detail

    Table 60. AbbVie Business Overview

    Table 61. AbbVie Graft Versus Host Disease (GVHD) Treatment Product

    Table 62. AbbVie Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023) & (US$ Million)

    Table 63. AbbVie Recent Development

    Table 64. Allergan Company Detail

    Table 65. Allergan Business Overview

    Table 66. Allergan Graft Versus Host Disease (GVHD) Treatment Product

    Table 67. Allergan Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023) & (US$ Million)

    Table 68. Allergan Recent Development

    Table 69. Anterogen Company Detail

    Table 70. Anterogen Business Overview

    Table 71. Anterogen Graft Versus Host Disease (GVHD) Treatment Product

    Table 72. Anterogen Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023) & (US$ Million)

    Table 73. Anterogen Recent Development

    Table 74. Astellas Pharma Company Detail

    Table 75. Astellas Pharma Business Overview

    Table 76. Astellas Pharma Graft Versus Host Disease (GVHD) Treatment Product

    Table 77. Astellas Pharma Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023) & (US$ Million)

    Table 78. Astellas Pharma Recent Development

    Table 79. Athersys Company Detail

    Table 80. Athersys Business Overview

    Table 81. Athersys Graft Versus Host Disease (GVHD) Treatment Product

    Table 82. Athersys Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023) & (US$ Million)

    Table 83. Athersys Recent Development

    Table 84. Caladrius Company Detail

    Table 85. Caladrius Business Overview

    Table 86. Caladrius Graft Versus Host Disease (GVHD) Treatment Product

    Table 87. Caladrius Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023) & (US$ Million)

    Table 88. Caladrius Recent Development

    Table 89. Eli Lilly Company Detail

    Table 90. Eli Lilly Business Overview

    Table 91. Eli Lilly Graft Versus Host Disease (GVHD) Treatment Product

    Table 92. Eli Lilly Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023) & (US$ Million)

    Table 93. Eli Lilly Recent Development

    Table 94. GlaxoSmithKline Company Detail

    Table 95. GlaxoSmithKline Business Overview

    Table 96. GlaxoSmithKline Graft Versus Host Disease (GVHD) Treatment Product

    Table 97. GlaxoSmithKline Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023) & (US$ Million)

    Table 98. GlaxoSmithKline Recent Development

    Table 99. Glenmark Company Detail

    Table 100. Glenmark Business Overview

    Table 101. Glenmark Graft Versus Host Disease (GVHD) Treatment Product

    Table 102. Glenmark Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023) & (US$ Million)

    Table 103. Glenmark Recent Development

    Table 104. Kadmon Holdings Company Detail

    Table 105. Kadmon Holdings Business Overview

    Table 106. Kadmon Holdings Graft Versus Host Disease (GVHD) Treatment Product

    Table 107. Kadmon Holdings Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023) & (US$ Million)

    Table 108. Kadmon Holdings Recent Development

    Table 109. Osiris Therapeutics Company Detail

    Table 110. Osiris Therapeutics Business Overview

    Table 111. Osiris Therapeutics Graft Versus Host Disease (GVHD) Treatment Product

    Table 112. Osiris Therapeutics Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023) & (US$ Million)

    Table 113. Osiris Therapeutics Recent Development

    Table 114. Sanofi Company Detail

    Table 115. Sanofi Business Overview

    Table 116. Sanofi Graft Versus Host Disease (GVHD) Treatment Product

    Table 117. Sanofi Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023) & (US$ Million)

    Table 118. Sanofi Recent Development

    Table 119. Takeda Company Detail

    Table 120. Takeda Business Overview

    Table 121. Takeda Graft Versus Host Disease (GVHD) Treatment Product

    Table 122. Takeda Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023) & (US$ Million)

    Table 123. Takeda Recent Development

    Table 124. Research Programs/Design for This Report

    Table 125. Key Data Information from Secondary Sources

    Table 126. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Graft Versus Host Disease (GVHD) Treatment Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Type: 2022 VS 2029

    Figure 3. Monoclonal Antibodies Features

    Figure 4. MTOR Inhibitors Features

    Figure 5. Tyrosine Kinase Inhibitors Features

    Figure 6. Thalidomide Features

    Figure 7. Etanercept Features

    Figure 8. Global Graft Versus Host Disease (GVHD) Treatment Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 9. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Application: 2022 VS 2029

    Figure 10. Acute Graft Versus Host Disease (aGvHD) Case Studies

    Figure 11. Chronic Graft Versus Host Disease (cGvHD) Case Studies

    Figure 12. Graft Versus Host Disease (GVHD) Treatment Report Years Considered

    Figure 13. Global Graft Versus Host Disease (GVHD) Treatment Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 14. Global Graft Versus Host Disease (GVHD) Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 15. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Region: 2022 VS 2029

    Figure 16. Global Graft Versus Host Disease (GVHD) Treatment Market Share by Players in 2022

    Figure 17. Global Top Graft Versus Host Disease (GVHD) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Graft Versus Host Disease (GVHD) Treatment as of 2022)

    Figure 18. The Top 10 and 5 Players Market Share by Graft Versus Host Disease (GVHD) Treatment Revenue in 2022

    Figure 19. North America Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 20. North America Graft Versus Host Disease (GVHD) Treatment Market Share by Country (2018-2029)

    Figure 21. United States Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. Canada Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. Europe Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 24. Europe Graft Versus Host Disease (GVHD) Treatment Market Share by Country (2018-2029)

    Figure 25. Germany Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. France Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. U.K. Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Italy Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Russia Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Nordic Countries Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Share by Region (2018-2029)

    Figure 33. China Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. Japan Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. South Korea Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. Southeast Asia Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. India Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Australia Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Latin America Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Latin America Graft Versus Host Disease (GVHD) Treatment Market Share by Country (2018-2029)

    Figure 41. Mexico Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Brazil Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. Middle East & Africa Graft Versus Host Disease (GVHD) Treatment Market Share by Country (2018-2029)

    Figure 45. Turkey Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. Saudi Arabia Graft Versus Host Disease (GVHD) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 47. Bristol-Myers Squibb Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

    Figure 48. Abbott Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

    Figure 49. AbbVie Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

    Figure 50. Allergan Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

    Figure 51. Anterogen Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

    Figure 52. Astellas Pharma Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

    Figure 53. Athersys Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

    Figure 54. Caladrius Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

    Figure 55. Eli Lilly Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

    Figure 56. GlaxoSmithKline Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

    Figure 57. Glenmark Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

    Figure 58. Kadmon Holdings Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

    Figure 59. Osiris Therapeutics Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

    Figure 60. Sanofi Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

    Figure 61. Takeda Revenue Growth Rate in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)

    Figure 62. Bottom-up and Top-down Approaches for This Report

    Figure 63. Data Triangulation

    Figure 64. Key Executives Interviewed